7 strategic priorities for MNC in Iran Pharma .

How should integrated business models of distributors be adapted to meet MNC priorities?

1. Data confirmed that top-line growth is the main strategic priority for MNC in Iran. 
2. Gaining market share is also measured important, while improving the bottom line is currently less of a priority. 
3. However the lowest priority is for bottom-line optimization which indicates that MNC in Iran are watching their cost base closely and will almost definitely re-prioritize their focus for next year due to sanctions lifted on September 2015. 
4. One common strategy is the ongoing penetration of existing molecules and reinforcing same sales channel. Many Blue chips ranked this as highest priority these action is because of hardships of their compliances for starting new business in Iran but Sanctions lifting will revive pharmaceutical sector and gaining share from new TA is most beneficiary than current low margin product with many local generic competitors. 
5. Finding a way to have a normal financial root with local partner. In spite of the fact that food and drugs are exempted from sanctions under international conventions, the impact of the sanctions on Iran over its nuclear program has been overwhelming, affecting the lives of millions of people on earth by blocking bank transactions  . 
6. Therapeutic expansion is also considered to be an important initiative, because of high CAGR of diabetes and cardiovascular incidence along with prevalence. 
7. The key levers for choosing strategy in Iran market is to having intelligence of market via local partner who has close collaboration with stakeholders.